PUMA BIOTECHNOLOGY INC (PBYI) Stock Price

PBYIStock
$9.32+73.71%52W
Market Cap$481.10M
P/E14.62x
PEG Ratio
Div yield
Beta1.24

PBYI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)25.28%
Price vs S&P 500 (4W)11.38%
VGM Score59.17
P/E Ratio (Annual)14.62x

PBYI Earnings Surprise History

Q2 250.15est. 0.07
Q3 250.21est. 0.09
Q4 250.29est. 0.23
Q1 26-0.04est. -0.13
Q2 260.20est. 0.07

PBYI Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
2.17
2.17
2.17
2.17

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
PBYIPUMA BIOTECHNOLOGY INC
BDB$9.32
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About PUMA BIOTECHNOLOGY INC

Puma Biotechnology is an oncology-focused biopharmaceutical company that commercializes NERLYNX, an oral medication for HER2-positive breast cancer, and is developing alisertib, an aurora kinase A inhibitor. The company targets improvements in cancer treatment outcomes through its portfolio of targeted therapies.